Ultragenyx Pharmaceutical Inc. (RARE) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 136M | 207M | 159.93M | 166.5M | 139.29M | 164.88M | 139.49M | 147.03M | 108.83M | 127.39M | 98.05M | 108.31M |
| Revenue Growth % | -2.36% | 25.55% | 14.65% | 13.24% | 27.99% | 29.42% | 42.27% | 35.75% | 8.3% | 23.27% | 8.1% | 21.23% |
| Cost of Goods Sold | 30M | 29M | 27.99M | 23M | 28.66M | 16.89M | 21.02M | 21.28M | 17.53M | 12.05M | 10.99M | 9.91M |
| COGS % of Revenue | 22.06% | 14.01% | 17.5% | 13.82% | 20.58% | 10.25% | 15.07% | 14.47% | 16.11% | 9.46% | 11.21% | 9.15% |
| Gross Profit | 106M | 178M | 131.94M | 143.49M | 110.63M | 147.98M | 118.47M | 125.75M | 91.3M | 115.34M | 87.06M | 98.39M |
| Gross Margin % | 77.94% | 85.99% | 82.5% | 86.18% | 79.42% | 89.75% | 84.93% | 85.53% | 83.89% | 90.54% | 88.79% | 90.85% |
| Gross Profit Growth % | -4.19% | 20.28% | 11.37% | 14.11% | 21.17% | 28.3% | 36.07% | 27.8% | 3.47% | 17.66% | 6.08% | 21.37% |
| Operating Expenses | 275M | 292M | 302.83M | 251.38M | 253.57M | 270.26M | 250.46M | 242.11M | 256.65M | 237.39M | 232.16M | 246.35M |
| OpEx % of Revenue | 202.21% | 141.06% | 189.35% | 150.98% | 182.04% | 163.92% | 179.55% | 164.67% | 235.82% | 186.35% | 236.77% | 227.45% |
| Selling, General & Admin | 88M | 89M | 86.62M | 86.65M | 87.8M | 82.5M | 80.35M | 80.6M | 78.16M | 76.83M | 74.92M | 81.4M |
| SG&A % of Revenue | 64.71% | 43% | 54.16% | 52.04% | 63.03% | 50.03% | 57.6% | 54.82% | 71.82% | 60.31% | 76.41% | 75.16% |
| Research & Development | 187M | 203M | 216.21M | 164.74M | 165.77M | 187.77M | 170.11M | 161.5M | 178.49M | 160.56M | 157.25M | 164.95M |
| R&D % of Revenue | 137.5% | 98.07% | 135.19% | 98.94% | 119.01% | 113.88% | 121.95% | 109.85% | 164% | 126.03% | 160.37% | 152.29% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -169M | -114M | -170.89M | -107.89M | -142.94M | -122.28M | -131.99M | -116.36M | -165.35M | -122.05M | -145.1M | -147.96M |
| Operating Margin % | -124.26% | -55.07% | -106.85% | -64.8% | -102.62% | -74.16% | -94.62% | -79.14% | -151.93% | -95.81% | -147.98% | -136.61% |
| Operating Income Growth % | -18.23% | 6.77% | -29.47% | 7.28% | 13.55% | -0.19% | 9.04% | 21.35% | -7.29% | 16.19% | 35.53% | -4.49% |
| EBITDA | -169M | -105.22M | -162.28M | -99.27M | -133.95M | -113.2M | -123.23M | -107.5M | -156.5M | -113.83M | -137.91M | -142.6M |
| EBITDA Margin % | -124.26% | -50.83% | -101.47% | -59.62% | -96.16% | -68.66% | -88.34% | -73.12% | -143.8% | -89.35% | -140.65% | -131.66% |
| EBITDA Growth % | -26.17% | 7.05% | -31.69% | 7.66% | 14.41% | 0.56% | 10.64% | 24.61% | -5.13% | 19.08% | 37.42% | -4% |
| D&A (Non-Cash Add-back) | 0 | 8.79M | 8.61M | 8.62M | 8.99M | 9.08M | 8.76M | 8.86M | 8.85M | 8.22M | 7.19M | 5.36M |
| EBIT | 0 | -114M | -165.39M | -99.96M | -135.43M | -117.88M | -117.5M | -114.78M | -154.38M | -109.56M | -141.33M | -143.72M |
| Net Interest Income | 0 | -12.49M | -8.29M | -8.25M | -7.51M | -5.97M | -4.98M | -8.56M | -7.02M | -8.78M | -11.78M | -9.41M |
| Interest Income | 6M | 6.51M | 5.86M | 5.79M | 6.83M | 9.55M | 10.73M | 7.4M | 8.82M | 8.55M | 5.88M | 5.96M |
| Interest Expense | -21M | 19M | 14.15M | 14.04M | 14.34M | 15.52M | 15.71M | 15.96M | 15.85M | 17.33M | 17.66M | 15.38M |
| Other Income/Expense | -15M | -14M | -8.65M | -6.12M | -6.83M | -11.13M | -1.23M | -14.38M | -4.88M | -4.84M | -13.9M | -11.14M |
| Pretax Income | -184M | -128M | -179.54M | -114M | -149.77M | -133.4M | -133.21M | -130.74M | -170.23M | -126.89M | -159M | -159.1M |
| Pretax Margin % | -135.29% | -61.84% | -112.26% | -68.47% | -107.52% | -80.91% | -95.5% | -88.92% | -156.41% | -99.61% | -162.16% | -146.89% |
| Income Tax | -1M | 1M | 873K | 947K | 1.31M | -19K | 303K | 858K | 455K | -3.7M | 650K | 732K |
| Effective Tax Rate % | 0.54% | -0.78% | -0.49% | -0.83% | -0.87% | 0.01% | -0.23% | -0.66% | -0.27% | 2.92% | -0.41% | -0.46% |
| Net Income | -185M | -129M | -180.41M | -114.95M | -151.08M | -133.38M | -133.52M | -131.6M | -170.68M | -123.19M | -159.65M | -159.83M |
| Net Margin % | -136.03% | -62.32% | -112.81% | -69.04% | -108.46% | -80.9% | -95.71% | -89.51% | -156.83% | -96.7% | -162.82% | -147.57% |
| Net Income Growth % | -22.45% | 3.29% | -35.12% | 12.65% | 11.49% | -8.28% | 16.37% | 17.66% | -4.09% | 18.86% | 34.87% | -1.05% |
| Net Income (Continuing) | -185M | -129M | -180.41M | -114.95M | -151.08M | -133.38M | -133.52M | -131.6M | -170.68M | -123.19M | -159.65M | -159.83M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 7M | 7M | 7M | 7M | 7M | 7M | 7M | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.84 | -1.29 | -1.81 | -1.17 | -1.57 | -1.39 | -1.40 | -1.52 | -2.03 | -1.52 | -2.23 | -2.25 |
| EPS Growth % | -17.2% | 7.19% | -29.29% | 23.03% | 22.66% | 8.55% | 37.22% | 32.44% | 12.88% | 29.63% | 36.29% | 0.44% |
| EPS (Basic) | -1.84 | -1.29 | -1.81 | -1.17 | -1.57 | -1.39 | -1.40 | -1.52 | -2.03 | -1.52 | -2.23 | -2.25 |
| Diluted Shares Outstanding | 100.6M | 99.9M | 99.77M | 98.46M | 96.29M | 95.68M | 95.49M | 86.58M | 84.29M | 81.12M | 71.66M | 70.9M |
| Basic Shares Outstanding | 100.6M | 99.9M | 99.77M | 98.46M | 96.29M | 95.68M | 95.49M | 86.58M | 84.29M | 81.12M | 71.66M | 70.9M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |